Best Management of Muscle Relaxation- Objective Monitoring
Summary
The purpose of this study is to demonstrate that the investigators can reduce residual paralysis to a very low incidence, and that the investigators can do this while preserving a role for the older and less expensive reversal agent neostigmine. The investigators consider this an evidence-based approach because previous reports clearly indicate that neostigmine is effective for reversal of the most shallow neuromuscular blocks, a level of block now referred to as minimal block. The Investigators also know from previous data that a substantial proportion of patients have minimal block. Sugammadex will be used when the block to be reversed is deeper than minimal, specifically when the objectively measured TOF-ratio is \<40%. The investigators hypothesize that this protocol will be associated with an incidence of residual paralysis of less than 3%. The investigators plan is to study 200 patients.
Timeline
- Start
- 2019-05-28
- Primary completion
- 2020-01-31
- Completion
- 2020-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neostigmine | Other / unclassified | — | — |
| Subject | Sugammadex | Other / unclassified | — | — |
| Background | Rocuronium | Other / unclassified | 0.6 mg/kg | — |